OBJECTIVE To study the inhibition of adhesion and invasion of SGC7901 cells into the ECM by integrinβ1 antisense oligodeoxynucleotide asODN.METHODS asODN and control ODN were transfected into SGC7901 cells using lipo...OBJECTIVE To study the inhibition of adhesion and invasion of SGC7901 cells into the ECM by integrinβ1 antisense oligodeoxynucleotide asODN.METHODS asODN and control ODN were transfected into SGC7901 cells using liposomes as vectors. The distribution of the ODN was followed by immunochemistry and changes in the expression of integrinβ1 mRNA and protein were determined by RT-PCR and FCM, respectively. The adhesion and invasion into the ECM were measured by the MTT and Boyden chamber methods, respectively.RESULTS Integrinβ1 asODN which was transfected into SGC7901 cells distributed evenly in the cytoplasm and nucleus. PCR and FCM revealed a weakened band at 489bp and a left-shift curve, respectively. Adhesion and invasion assays showed decreased activity with an inhibition rate of 54% and 76%. The extent of decrease induced by integrinβ1 asODN was larger than that caused by random control ODN (P<0.001).CONCLUSION Transfection of integrinβ1 asODN into SGC7901 cells induced a decrease in the expression of integrinβ1 mRNA and protein,resulting in a decrease in adhesion and invasion into the ECM, with a greater effect than random control ODN.展开更多
AIM: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). METHODS: From Apr.20...AIM: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). METHODS: From Apr.2002 to Feb. 2003, 52 patients were enrolled in this study. Chemotherapy was conducted with cyclophosphamide 600 mg·m^-2, vincristine 1.4 mg·m^-2,doorubicin 25mg·m^-2 on d 1 and prednisone 60 mg·d^-l for successive 5 d (standard CHOP). There were 6 courses, 3 wk each. Rituximab 375 mg·m^-2 was infused once a week, 2 d before the first course of chemotherapy (successive infusion) for 4 times on standard dose or for 6 times on extended dose. Or rituximab was infused once every 3 wk, 2 d before each CHOP (separated infusion) for 4 times on the schedule of standard dose or for 6 times on the extended dose. RESULTS: The complete response (CR) rate (60%) and total effective (100%) were achieved in 50 patients who were evaluated for efficacy, respectively. And among 34 patients in Ann Arbor stage Ⅲ and Ⅳ, 15 patients were completely relieved. The complete effective rate was 44%. Fifty patients were followed-up for (8±s 5) wk, 2-30wk and estimated progress free survival (PFS) rate of 16 wk was 87 %. Standard and extend regimen were not different in effect, as well as the separated or concentrated infusion of rituximab (P>0.05). The regimen could be well tolerated, and the major adverse reactions were infusion-related response (32 % ) and hematological toxicities (20 %). CONCLUSION:Rituximab in combined with CHOP can be successfully applied to the therapy of initially diagnosed diffuse large B cell lymphoma, with high CR rate and mild adverse reactions.展开更多
文摘OBJECTIVE To study the inhibition of adhesion and invasion of SGC7901 cells into the ECM by integrinβ1 antisense oligodeoxynucleotide asODN.METHODS asODN and control ODN were transfected into SGC7901 cells using liposomes as vectors. The distribution of the ODN was followed by immunochemistry and changes in the expression of integrinβ1 mRNA and protein were determined by RT-PCR and FCM, respectively. The adhesion and invasion into the ECM were measured by the MTT and Boyden chamber methods, respectively.RESULTS Integrinβ1 asODN which was transfected into SGC7901 cells distributed evenly in the cytoplasm and nucleus. PCR and FCM revealed a weakened band at 489bp and a left-shift curve, respectively. Adhesion and invasion assays showed decreased activity with an inhibition rate of 54% and 76%. The extent of decrease induced by integrinβ1 asODN was larger than that caused by random control ODN (P<0.001).CONCLUSION Transfection of integrinβ1 asODN into SGC7901 cells induced a decrease in the expression of integrinβ1 mRNA and protein,resulting in a decrease in adhesion and invasion into the ECM, with a greater effect than random control ODN.
文摘AIM: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). METHODS: From Apr.2002 to Feb. 2003, 52 patients were enrolled in this study. Chemotherapy was conducted with cyclophosphamide 600 mg·m^-2, vincristine 1.4 mg·m^-2,doorubicin 25mg·m^-2 on d 1 and prednisone 60 mg·d^-l for successive 5 d (standard CHOP). There were 6 courses, 3 wk each. Rituximab 375 mg·m^-2 was infused once a week, 2 d before the first course of chemotherapy (successive infusion) for 4 times on standard dose or for 6 times on extended dose. Or rituximab was infused once every 3 wk, 2 d before each CHOP (separated infusion) for 4 times on the schedule of standard dose or for 6 times on the extended dose. RESULTS: The complete response (CR) rate (60%) and total effective (100%) were achieved in 50 patients who were evaluated for efficacy, respectively. And among 34 patients in Ann Arbor stage Ⅲ and Ⅳ, 15 patients were completely relieved. The complete effective rate was 44%. Fifty patients were followed-up for (8±s 5) wk, 2-30wk and estimated progress free survival (PFS) rate of 16 wk was 87 %. Standard and extend regimen were not different in effect, as well as the separated or concentrated infusion of rituximab (P>0.05). The regimen could be well tolerated, and the major adverse reactions were infusion-related response (32 % ) and hematological toxicities (20 %). CONCLUSION:Rituximab in combined with CHOP can be successfully applied to the therapy of initially diagnosed diffuse large B cell lymphoma, with high CR rate and mild adverse reactions.
